You are here:

Siponimod for secondary progressive MS: help us make the case to NICE

Published on

NICE is assessing siponimod for secondary progressive MS (SPMS) to decide whether it should be prescribed by the NHS in England and Wales.  Scotland and Northern Ireland will carry out separate appraisals.

The MS Trust will be explaining to NICE why we think siponimod should be made available on the NHS. To help us make a strong case, we want to hear your experiences of living with SPMS, your views on current NHS care for SPMS and your thoughts on siponimod.

We’d like to hear from you if you live in the UK and

  • you have secondary progressive MS
  • you have a different type of MS, but would like to add your views
  • you are a partner / friend / relative / carer of someone with SPMS
  • you are a health professional providing care for people with SPMS

Tell us what you think by completing this short questionnaire by 17 September.

Find out more

Print this page